Intellia cuts HAE attacks 87%

- Intellia Therapeutics reported a Phase 3 win for its in‑vivo CRISPR treatment lonvo‑z in hereditary angioedema, showing large clinical benefit versus placebo. (cnbc.com) - The headline result: attacks fell by 87% versus placebo and 62% of treated patients were attack‑free in the late‑stage study. (ts2.tech) - Intellia already holds Orphan Drug and RMAT designations, which fast‑tracks regulatory pathways and pushes a potential approval timeline toward 2027. (biospace.com)